TACR1 and cancer: In this line, a recent review has focused on the biological and chemical aspects of peptide and non-peptide NK-1R ligands (e.g., aprepitant) as radiopharmaceuticals and on the application of these compounds in targeted radionuclide cancer therapy [6].